- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01958242
Effect of Blood Harvesting and Administration at End of CPB on Coagulation Profile
The Effect of Preoperative Blood Harvesting and Its Re-administration at the End of Cardio-pulmonary Bypass on the Coagulation Profile in the Pediatric Population Undergoing Open Heart Surgery.
Blood transfusions after pediatric heart surgery is a relatively common practice occurring in up to 46% of patients, however its use has been associated with increased morbidity. In the pediatric population undergoing heart surgery transfusion of homologous blood is usually required due to the mismatch between the priming volume of the cardiopulmonary bypass circuit and the patients own blood volume. Several strategies have been proposed in order to minimize the use of blood products. The effect of pre-operative harvest of fresh whole blood in the adult population has shown a beneficial platelet protective effect, however concerns have been risen that the amount of volume needed in order to sequester a significant amount of platelets would be prohibit ally high in a cardiac surgical patient. Fresh blood harvesting has not been evaluated in the pediatric population.
The purpose of the present study would be to evaluate the safety and efficacy of pre-operative blood harvesting in the pediatric population undergoing open heart surgery. Fresh whole blood will be harvested from the patient prior to the initiation of cardiopulmonary bypass and will be returned to the patient after the discontinuation of CPB prior to the administration of prominent. Parameters that will be evaluated will include, patient characteristic, operative and post-operative parameters, coagulation profiles and the use of postoperative blood products.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All pediatric patients undergoing open heart surgery at our institution will be randomized based on the last digit of their identification number (even or odd numbers) to undergo pre-operative whole blood harvesting (PBH). Informed consent will be obtained from the parents at the time of surgical informed consent acquisition.
After scrubbing and draping of the patient the first set of blood samples will be obtained for baseline.
Circuit priming will be performed using plasmalyte , and the prime will be adjusted to have a calculated bypass hematologic 27%, taking into consideration the amount of blood harvested.
Once the patient is connected to the CPB circuit, harvested blood will be taken from the venous line before its passage through the oxygenator, while crystalloids from the circuit will be infused through the arterial line in order to maintain adequate blood pressure. Once the amount of 15cc/kg of blood is harvested, CPB will be initiated and the operation will be carried out in the usual manner. Blood will be kept at room temperature (18°C), gently stirred (not shaken).
At the end of the operation, veno-venous ultrafiltration will be performed, targeting a duration of 10 minutes. The harvested blood will be administered at the end of ultrafiltration in conjunction to the administration of protamine. Blood samples will be obtained at various time points. Complete blood count, coagulation profile (PT/PTT), and platelet function tests will be performed. Pre-operative and operative characteristics will be recorded .
In the intensive care unit, the patient will be continuously followed until his discharge from the hospital and post-operative parameters will be recorded. Blood and blood product administration will be based on our ICU protocol and at the discretion of the attending physician. Generally, blood will be administered to single ventricle patients if their hemoglobin levels will be below 12 mg%, while in the 2 ventricle patients a threshold of 9mg% will be set. Administration of blood products will be performed if there will be signs of clinical bleeding with overt signs of coagulopathy (INR > 2, fibrinogen < 100, platelets < 50,000).
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petah Tikva, Israel, 49202
- Schneider Children Medical Center of Israel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All pediatric patients undergoing heart surgery
Exclusion Criteria:
- Unstable patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Preoperative blood harvesting
|
There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in coagulation profile
Time Frame: Immediate post operative
|
Coagulation studies will be measured before and after the intervention
|
Immediate post operative
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gabriel Amir, MD, SCMCI
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 7192
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Changes
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceCompletedBody Weight Changes | Dietary Modification | Gastrointestinal Microbiome | Bread | Hematologic TestsIsrael
-
Texas Tech UniversityEHP LabsCompletedBody Weight Changes | Body Composition Changes | Anthropometric Changes | Metabolism Changes | Hemodynamic ChangesUnited States
-
CytokineticsCompletedQT Intervals Changes | QTc Intervals ChangesUnited Kingdom
-
Merck Sharp & Dohme LLCCompleted
-
University of MiamiSherman Fairchild FoundationCompletedChanges in Physical Fitness | Changes in Diet, Food, and Nutrition Habits | Changes in Child HealthUnited States
-
Karius, Inc.Stanford UniversityCompletedNeutropenia | FeverUnited States
-
University of Colorado, DenverWithdrawn
-
The University of Hong KongCompletedPlatelet Dysfunction | Hemodilution | Mild Hypothermia | NSAID | DesmopressinChina
-
Swiss Pediatric Oncology GroupBayer; GlaxoSmithKline; Swiss Cancer LeagueTerminatedCancer | Neutropenia | FeverGermany, Netherlands, Switzerland
-
Enzon Pharmaceuticals, Inc.WithdrawnHematologic Diseases | Cancer | Neutropenia | Fever
Clinical Trials on Preoperative blood harvesting
-
Clinical Hospital Centre ZagrebCompletedHip Arthroplasty | Transfusion
-
Aga Khan UniversityCompletedOrthopedic Disorder
-
University of MilanCompletedGingival Recession | Palate; WoundItaly
-
Medical University InnsbruckRecruitingCoronary Artery DiseaseAustria, Germany, Switzerland
-
Boston Scientific CorporationHerzzentrum DresdenTerminatedCoronary Artery DiseaseGermany
-
Zonguldak Bulent Ecevit UniversityCompleted
-
Meshalkin Research Institute of Pathology of CirculationCompletedAutovenous Conduit for Coronary Artery Bypass Grafting
-
Kerckhoff KlinikCompletedCABG Graft IntegrityGermany
-
China National Center for Cardiovascular DiseasesUnknown
-
Seoul National University HospitalCompletedMyocardial Infarction | Stable Angina | Unstable Angina | Triple Vessel DiseaseKorea, Republic of